We have several new products to offer, such us mono-dose of 18 F, FDG GLUCOMPET. You will also have the opportunity to attend the presentation of an innovative service such as PET-MOBILE. We will be introducing some new technological concepts in the diagnosis and molecular therapy filed such us Proton Therapy and BNCT (Boron Therapy).

In this extraordinary atmosphere, you will be offered some Italian wine and will have the chance to talk to our professional advisers. We will do our best to offer you an interesting meeting and a blend of science, medicine and good taste.

Acom Group

Our Scientific Director, Dr. Gianluca Valentini, will take a spech at 41st Annual Conference of Society of Nuclear Medicine (India).

Acom Group

If you want try it in a clinical trial contact us by community. An interesting case report showed in reserved area, suggest a specific binding with melanoma brain metastasis.

If you want read it, please joint in to free Acom community

Acom Group

The most important innovation is Acom community . It would be a blog where exchange information and knowledge, new ideas and challenges between scientist and researcher about new isotopes and new radiopharmaceuticals, new technologies, and clinical trial outcomes.

Acom community would be a rendezvous for physicians, researchers, physicists and anyone who have an interest all around Nuclear Medicine. Otherwise visit web site and enter in Community.

Acom Group

Cyclotron-based neutron irradiation facility for BNCT experimental applications

C.Ceballos ¹², J. Esposito¹, E. Fagotti¹, P.Colautti¹, D. Moro¹³,

A. Pisent¹, P. Panichelli4, G. Valentini4.

1) INFN, Laboratori Nazionali di Legnaro, Viale dell’Università 2, I-35020 Legnaro, PD, Italy.

2) Centro de Aplicaciones Tecnlógicas y Desarrollo Nuclear, 5ta y 30, Miramar, Playa, Ciudad Habana, Cuba.

3) Dipartimento di fisica dell’Università di Padova, via Marzolo 8, I-35131 Padova, Italy

4) ACOM spa. Montecosaro Scalo, I-62010, MC, Italy.

A design of an irradiation facility to be used for Boron Neutron Capture Therapy (BNCT) experimental trials on cell cultures and small animals, using an accelerator-based neutron source is developed. The neutron converter is based on a cyclotron-produced deuteron beam (9 MeV, 40 µA) impinging on a beryllium target. The cyclotron considered here, is already used for the production of radioactive isotopes, devoted to medical applications. The design includes the deuteron beam transport line, the beryllium target, the neutron beam shaping assembly, and finally the irradiation room. The characterizations of the therapeutic beam and the dosimetric calculations outside the irradiation room have been performed by means of MCNPX transport code using in-air figure of merits. The study reveled that, even using a low power accelerator (0.36 kW), a thermal flux level of the order of 108 cm-2s-1, having a thermal-to-total neutron flux ratio of 0.92 is achieved.

Acom Group

We have required to the relevant regulatory Competent Authority the authorisation for a phase three clinical trial to accurately detect early bone metastases in case of prostate cancer, that might not be detected using conventional available methods.

Would you like to be an investigator of this clinical trial? What about this in your experience? Contact us for any questions, ideas or doubt in regard to this argument.

Acom Group